Medication News

BUYINS.NET: PP, DB, FCF, IMH, LFC, SPF Have Been Added To Naked ...

Pipex Pharmaceuticals, Inc. (AMEX: PP) a development stage specialty pharmaceutical company, engages in the development of proprietary late-stage drug candidates for the treatment of neurologic and fibrotic diseases. Its lead drug candidate includes COPREXA, an oral and anti-copper therapeutic that has completed Phase III clinical trial in neurologically-presenting Wilson's disease. The company has also completed phase II clinical trials for COPREXA, which would be used for the treatment of refractory idiopathic pulmonary fibrosis, a progressive fibrotic lung disease. In addition, it is conducting Phase II clinical trial for COPREXA, which would be used for the treatment of primary biliary cirrhosis. The company completed Phase II clinical trial for TRIMESTA, an oral estriol that is used for the treatment of relapsing-remitting multiple sclerosis, a life threatening autoimmune disease. It also conducts a phase I/II clinical trial for Anti-CD4 802-2 used for the prevention of severe graft versus host diseases, as well as conducts preclinical studies for the treatment of autoimmune diseases. In addition, the company conducts Phase II clinical trial of CORRECTA, a clotrimazole enema for the treatment of refractory acute pouchitis. Further, it plans to conduct Phase II clinical trial for EFFIRMA, which is an oral flupirtine for the treatment - more available